Press Releases

Topics:
  TITLE DATE  
 
 

Nymox Announces $16.25 Million Equity Financing With Qualified Long- Term Investors

2018-04-12

 
 
Topic:  Financial
 
 

Nymox Pharmaceutical Corporation is pleased to announce today that the Company has successfully secured $16.25 million in new equity capital with several professional high net worth investors.

 
 
 

New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology

2018-04-10

 
 
Topic:  Other Topics
 
 

A new online published commentary about Nymox’s Fexapotide 2018 clinical trial results publication in World Journal of Urology has newly appeared today on UroToday in its "Beyond the Abstract" section.

 
 
 

Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3

2018-03-01

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological Association Mid-Atlantic Section, in Amelia Island FL March 3.

 
 
 

Nymox Announces US NDA for Fexapotide for BPH

2018-02-05

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation announced today that the Company will submit a New Drug Application (NDA) for Fexapotide Triflutate for the treatment of BPH in the US.

 
 
 

Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology

2018-01-30

 
 
Topic:  Other Topics
 
 

Nymox Pharmaceutical Corporation reports today that the results of Phase 3 clinical studies of Fexapotide Triflutate undertaken from 2009-2016 are now published in World Journal of Urology.

 
 
 

Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men

2018-01-22

 
 
Topic:  R&D: Cancer Treatments
 
 

Nymox Pharmaceutical Corporation reported today top-line 5-year results from Nymox's U.S. Study NX03-0040.

 
 
 

Nymox Fexapotide Symposium and Panel Discussion at American Urological Association South Central Sectional Annual Meeting in Naples FL

2017-11-27

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, South Central Section in Naples, November 27.

 
 
 

Nymox Fexapotide Symposium and Panel Discussion at American Urological Association North Central Sectional Annual Meeting in Scottsdale

2017-11-16

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, North Central Section in Scottsdale, November 15.

 
 
 

Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association North Central Section Annual Meeting in Scottsdale AZ November 15

2017-11-10

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological Association North Central Section, in Scottsdale AZ next week.

 
 
 

Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana

2017-11-07

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report on the two data presentations which were held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, New York Section in Havana, November 6.

 
  Total   391   Records   First   Previous   1 of 40   Next   Last      Go